Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Divergent Cardiac and Renal Outcomes by Systolic Blood Pressure in HFrEF.

BACKGROUND Elevated systolic blood pressure (SBP) is associated with paradoxically lower mortality in heart failure with reduced ejection fraction (HFrEF), but whether this reflects underlying pathophysiology or residual confounding remains uncertain. Because higher SBP is also a risk factor for kidney failure, we test...

H. Sheriff, Q. Zeng-Treitler, John G. F. Cleland et al. · 0 citations
Oct 2026

Patiromer Efficacy across Kidney Function and Hyperkalemia Subgroups in Heart Failure and Reduced Ejection Fraction: A DIAMOND Post Hoc Analysis.

Patiromer reduced serum potassium across baseline kidney function and hyperkalemia subgroups, with greater effect in patients with reduced kidney function and baseline hyperkalemia, which suggest potential heterogeneity in potassium-lowering effects of patiromer across subgroups.

A. Kalogeropoulos, A. M. Rashid, S. Anker et al. · 0 citations
Review Open access Oct 2026

Cancer therapy-related cardiovascular toxicity testing: an overview of experimental preclinical in vitro models and how to best use them in combination with animal models, omics and AI-based in silico approaches

Cancer therapy-related cardiovascular toxicity (CTR-CVT) remains a major contributor to morbidity and mortality among cancer survivors. While advances in cancer therapy have significantly improved survival rates, many of these treatments come at the cost of unintended cardiovascular damage. This creates a complex and...

Anaëlle Fratard, Georgia Kalogianni, N. Kindt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.